Jennifer Cohn1, Teri Roberts, Valerianna Amorosa, Maud Lemoine, Andrew Hill. 1. aDivision of Infectious Diseases, University of Pennsylvania bMédecins Sans Frontières, Geneva, Switzerland cDivision of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA dDepartment of Hepatology, St Mary's Hospital, Imperial College, London, London eDepartment of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK.
Abstract
PURPOSE OF REVIEW: Approximately 150-175 million people are infected with hepatitis C virus (HCV). Until very recently, the complexity, cost and poor efficacy and tolerability of pegylated interferon and ribavirin (PEG-RBV) treatment have hindered scale up in low-income and middle-income countries (L&MICs). Similarly, the diagnostic and monitoring algorithm associated with PEG-RBV has been expensive and complicated because of the poor efficacy and frequency of adverse drug effects of PEG-RBV therapy. This article provides an overview of the potential changes to the diagnosis and monitoring algorithm and describes key promising tools in the diagnostics pipeline. RECENT FINDINGS: Interferon-free direct-acting antiviral (DAA) therapy sets the stage to significantly simplify laboratory requirements and make the overall diagnostic package much less expensive. Diagnostic simplification and cost-reduction will be key to enable implementation of HCV screening and treatment in L&MICs. SUMMARY: There is the potential to introduce simplified monitoring for hepatitis C. Antigen testing could be used as a replacement for HCV RNA PCR tests, to establish active infection and then to prove cure after stopping DAA treatment. If new DAA treatments can be shown to be pan-genotypic, genotyping may no longer be required.
PURPOSE OF REVIEW: Approximately 150-175 million people are infected with hepatitis C virus (HCV). Until very recently, the complexity, cost and poor efficacy and tolerability of pegylated interferon and ribavirin (PEG-RBV) treatment have hindered scale up in low-income and middle-income countries (L&MICs). Similarly, the diagnostic and monitoring algorithm associated with PEG-RBV has been expensive and complicated because of the poor efficacy and frequency of adverse drug effects of PEG-RBV therapy. This article provides an overview of the potential changes to the diagnosis and monitoring algorithm and describes key promising tools in the diagnostics pipeline. RECENT FINDINGS: Interferon-free direct-acting antiviral (DAA) therapy sets the stage to significantly simplify laboratory requirements and make the overall diagnostic package much less expensive. Diagnostic simplification and cost-reduction will be key to enable implementation of HCV screening and treatment in L&MICs. SUMMARY: There is the potential to introduce simplified monitoring for hepatitis C. Antigen testing could be used as a replacement for HCV RNA PCR tests, to establish active infection and then to prove cure after stopping DAA treatment. If new DAA treatments can be shown to be pan-genotypic, genotyping may no longer be required.
Authors: Mário F Neto; Matthew A Butzler; Jennifer L Reed; Xiang Rui; Mark J Fisher; David M Kelso; Sally M McFall Journal: J Virol Methods Date: 2017-06-30 Impact factor: 2.014
Authors: Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore Journal: Int J Drug Policy Date: 2017-07-03
Authors: J Morgan Freiman; Trang M Tran; Samuel G Schumacher; Laura F White; Stefano Ongarello; Jennifer Cohn; Philippa J Easterbrook; Benjamin P Linas; Claudia M Denkinger Journal: Ann Intern Med Date: 2016-06-21 Impact factor: 25.391
Authors: Zobair M Younossi; Louis L LaLuna; John J Santoro; Flavia Mendes; Victor Araya; Natarajan Ravendhran; Lisa Pedicone; Idania Lio; Fatema Nader; Sharon Hunt; Andrei Racila; Maria Stepanova Journal: BMC Gastroenterol Date: 2016-04-04 Impact factor: 3.067